Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2023-10-20 Board/Management Inform…
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Change in Medivir's Board of Directors
Board/Management Information Classification · 99% confidence The document explicitly announces a change in the company's board of directors: 'Change in Medivir's Board of Directors' and states that a board member, Anette Lindqvist, is leaving her position. This directly corresponds to the definition of Board/Management Information (MANG), which covers 'Announcement of changes in the company's board of directors or senior management.' The document is short and contains the core announcement, not just a link to a report.
2023-10-20 English
Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima
Earnings Release Classification · 95% confidence The document is a press release announcing 'promising interim data' regarding a clinical study (phase 1b/2a) for a drug candidate (fostrox) in HCC patients. It details efficacy results (complete response, partial response, stable disease) and mentions that the full data will be presented at an upcoming scientific congress. It also announces a related Expert Perspectives Webcast. This structure—announcing key clinical/scientific results outside of a formal quarterly filing (like 10-K or IR)—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses purely on clinical trial results and scientific updates rather than comprehensive financial performance for a period, it is best classified as an Earnings Release (ER) as it serves as the primary communication of recent operational/scientific milestones, often released concurrently with or instead of a formal financial report when major news breaks. It is not a full financial report (10-K or IR), nor is it just an announcement of a report (RPA). FY 2023
2023-09-04 English
Medivir rapporterar lovande interimsdata, som inkluderar ett komplett tumörsvar, i fas 1b/2a HCC-studien med fostrox i kombination med Lenvima
Earnings Release Classification · 95% confidence The document is a press release from Medivir AB announcing 'lovande interimsdata' (promising interim data) regarding the safety and efficacy of their drug candidate fostrox in an ongoing Phase 1b/2a HCC study. It details specific clinical results (tumor response rates) and mentions that the full data will be presented at a 'kommande vetenskaplig kongress' (upcoming scientific congress). It also announces a related webcast scheduled for a future date. This structure—announcing key clinical trial results and updates outside of a formal quarterly/annual filing—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical milestones. Since it focuses purely on clinical trial results and operational updates rather than comprehensive financial statements (which would suggest IR or 10-K), and it is an initial announcement of results (interim data), the most appropriate classification is Earnings Release (ER), as these often include operational highlights alongside financial ones, or in the case of biotech, clinical highlights serve as the primary 'earnings' announcement. Given the focus on interim clinical data release, ER is the best fit among the options provided, as it is an initial release of performance metrics. FY 2023
2023-09-04 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Medivir AB covering the period January to June 2023. It contains detailed financial summaries (income statements, cash flow, balance sheet items), management commentary, and operational updates on clinical trials. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2023
2023-08-18 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2023'. It contains comprehensive financial summaries for the quarter and the six-month period, including net turnover, EBITDA, earnings per share, and cash flow data. It also includes detailed management commentary, project updates, and operational highlights. As it provides substantive financial statements and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2023
2023-08-18 English
Change in the number of shares and votes in Medivir AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly announces a 'Change in the number of shares and votes in Medivir AB (publ)' due to a share issue and reclassification of shares. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). It is not an earnings release, an annual report, or a dividend notice. The document confirms the final share count as of May 31, 2023, following the capital event.
2023-05-31 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.